产品
编 号：F384544
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 541502-14-1
产品详情
生物活性：
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
体内研究：
Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model.Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model.Animal Model:Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg; 3 times per week
Result:Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells.Repressed PY-STAT3 levels in H1650 cells.Inhibited the growth of tumors with H322 and CAF cells.Inhibited the growth of tumors with H1650 and CAF cells.
Animal Model:Female NOD-SCID mice with MCF-7 tumor
Dosage:20 mg/kg
Administration:Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
Result:Blocked MCF-7 engraftment, induced regressions in 90% of tumors.
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
体内研究：
Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model.Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model.Animal Model:Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg; 3 times per week
Result:Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells.Repressed PY-STAT3 levels in H1650 cells.Inhibited the growth of tumors with H322 and CAF cells.Inhibited the growth of tumors with H1650 and CAF cells.
Animal Model:Female NOD-SCID mice with MCF-7 tumor
Dosage:20 mg/kg
Administration:Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
Result:Blocked MCF-7 engraftment, induced regressions in 90% of tumors.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备